Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.07.31.666261

B7-H4 Binds Galectin-9 Glycosylation-Dependently and Attenuates Galectin-9-Mediated CD28/AKT Activation and T Cell Death

Abstract

B7-H4, a member of the B7 family, is broadly expressed on various cancer cells and has been implicated in negative immune regulation, particularly in suppressing anti-tumor immunity. However, the receptor for B7-H4 and the molecular mechanisms underlying its immunoinhibitory effects remain poorly understood. In this study, using peritoneal immune cells from mice adoptively transferred with OVA-expressing tumor cells and OVA-specific OT-1 T cells, we identified Galectin-9 (Gal-9) as a binding partner for B7-H4 and elucidated its role in modulating T cell responses through this interaction. We demonstrated that glycosylation in the IgC domain of B7-H4 is required for its binding to Gal-9; while the N-terminal carbohydrate recognition domain (N-CRD) of Gal-9, including the R65 residue in the N-CRD, is essential for this interaction. Additionally, we found that other B7 family members (B7.1, B7.2, B7-H2, and B7-DC) and immune cell surface receptors (CD28, 2B4, CD226, and SLAMF1) also bind to Gal-9 at comparable levels to B7-H4 and T cell immunoglobulin mucin receptor 3 (TIM-3). In vitro functional assays revealed that B7-H4 inhibits Gal-9-induced activation of CD28 downstream signaling and reduces Gal-9-mediated T cell death. In vivo, Gal-9 deficiency in mice resulted in a significant reduction in the proportion of splenic CD4+ T cells, whereas B7-H4 deficiency exhibited no observable phenotype. Furthermore, B7-H4 and Gal-9 double-knockout mice displayed no additional phenotype differences compared to Gal-9 single-knockout mice. Notably, tumor growth following tumor cell challenge was unaffected in all three knockout models (Gal-9 single-, B7-H4 single-, or double-knockout). Collectively, these findings suggest that B7-H4, other B7 family members, Gal-9, and T cell surface immune receptors form a complex regulatory network that modulates T cell activity and anti-tumor responses, although no single member exerts a major effect. This study provides a detailed molecular characterization of the interaction between B7-H4 and Gal-9 and identifies other previously unknown Gal-9 binding partners, offering valuable insights into the intricate regulatory network involving these molecules.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wang, R. Z., Yang, F., SUI, J.. 2025-08-01. B7-H4 Binds Galectin-9 Glycosylation-Dependently and Attenuates Galectin-9-Mediated CD28/AKT Activation and T Cell Death. https://doi.org/10.1101/2025.07.31.666261

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗